ProBioGen, Eucodis Sign Agreement
News Apr 20, 2016
ProBioGen and Eucodis Bioscience have announced the signature of an exclusive license agreement on C-LiNK (CTAT), an innovative, site-specific ADC conjugation technology. Under the agreement ProBioGen gains exclusive rights to commercialize Eucodis’ enzymatic C-terminal linking technology, and to offer it, together with its antibody development services, royalty-free to ADC-developing parties.
ProBioGen’s CEO, Dr. Wieland Wolf, commented: “This agreement is an excellent match between Eucodis’ enzyme engineering expertise and ProBioGen’s therapeutic protein-optimizing technologies and we look much forward to position C-LiNK and our contract manufacturing services right in the middle of the hot ADC field”.
Dr. Karl Hübler, CEO of Eucodis explained: “We see a huge potential for C-LiNK in Biopharma, especially in ADC development, but our expertise is engineering enzymes. Therefore, by teaming up with ProBioGen, our ADC conjugation technology will certainly get a much wider and quicker access to the community of therapeutic protein developing companies and we are convinced that our agreement with ProBioGen will result in fruitful collaborations within the industry.”
ProBioGen’s Chief Scientific Officer, Dr. Volker Sandig, added: “This innovative ADC technology, which efficiently attaches any payload enzymatically via a pure peptide linker -as short as two amino acids-, blends perfectly into our portfolio of robust cell line/product engineering technologies and manufacturing capabilities. The 1-step C-LiNK coupling technology will further open up the development space for ADCs and represents a competitive alternative to other Antibody-Drug Conjugate Technologies.”
Dr. Jan Modregger, Eucodis’ Head of R&D stated: “Based on a trypsin variant engineered to enforce formation of a new peptide bond, our ADC conjugation technology links toxins or other molecules to the C-terminus of either antibody chain, without disturbing the native antibody structure. The outcome is a defined Drug-Antibody Ratio at high yield with low enzyme requirements and it offers on top the flexibility to add different payloads to separate sites in future ADCs.”
Sweet Spot of Activity in Immune System Key to Fighting CancerNews
Scientists have shown how stimulating a specific location on the surface of immune cells can be targeted with antibodies to help in their fight against cancer.READ MORE
Putting Proteins in Their Proper PlaceNews
Everything in the cell has its right place. This includes certain molecules called RNA-binding proteins. When these are misplaced, they can end up causing dangerous clumps that are typical of diseases like ALS. A new study has found a way to send these proteins home.READ MORE
Comments | 0 ADD COMMENT
16th Annual Conference on Laboratory Medicine and Pathology
Sep 17 - Sep 18, 2018